Nowadays, it is established that aberrant activation or overexpression of HDAC isoenzymes trigger disruptions of the functional acetylation landscape, therefore contributing to the development of numerous cancers including CML [8, 9]. Here, HDAC9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.